IO Biotech begins phase III trial with partner MSD

IO Biotech joins forces with partner MSD in the development of a new therapy for the treatment of skin cancer in combination with IO Biotech's lead candidate Keytruda. A big phase III trial now commences, and if successful, IO Biotech maintains commercial rights.
Photo: ANDREAS GEBERT/REUTERS / X06742
Photo: ANDREAS GEBERT/REUTERS / X06742
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN

A possible breakthrough in the treatment of metastatic melanoma patients could be on the way. Around 290,000 people are diagnosed with the skin cancer every year.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading